Quintiles Wins Best CRO In Vaccine Excellence Awards 2012

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--

Quintiles, the world's leading global biopharmaceutical services company, today announced that it has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards 2012. Presented at the World Vaccine Congress now under way in Washington, D.C., the awards recognize and celebrate the leaders, innovators and pioneers in the vaccines industry.

“This is a great honor to be recognized as the Best CRO at the World Vaccine Congress,” said Dr. Ellen Vigdorth, VP Allergy, Respiratory, Infectious Diseases and Vaccines. “It is a huge achievement and underscores our commitment to the development of quality vaccines and anti-infective products.

Customers voted for their preferred CRO prior to the World Vaccine Congress; a judging panel then made its selection based on the following criteria:

• Range of services provided in niche and core therapeutic areas;
• Methods of performance improvement or introduction of new services;
• Attention to and quality of relationships with clients;
• Reaching of milestones and final/ongoing outcomes; and
• Building and maintaining existing and long-term partnerships.

Dr. Vigdorth also presented on “Climate change in vaccine trials: Moving from a one-size-fits-all to a custom fit in operational delivery” on Wednesday, April 11 at 10:25. In the discussion, Dr. Vigdorth explored the critical role of epidemiology, temporal requirements and local customs integration into design, planning and delivery for successful vaccine trials. The presentation delved into the possible challenges and how to overcome them in a global environment through the discussion of four vaccine case studies—H1N1 influenza, pneumococcal disease, neglected diseases and malaria.

This award comes shortly after Quintiles was named, for the second year running, the 2012 Asia Pacific CRO of the Year at the BioPharma Convention Awards.

Since 2007, Quintiles has provided clinical services for more than 150 vaccine trials involving almost 300,000 patients worldwide.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients' lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.